Firdapse (previously Zenas)
amifampridine · SERB SA
EXCEPTIONAL CIRCUMSTANCES AUTHORISED IN THE EUWhat Firdapse (previously Zenas) is used for
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Firdapse (previously Zenas)
- Active substance
- amifampridine
- Disease area
- Lambert-Eaton Myasthenic Syndrome
- Medicine group
- Other nervous system drugs
- ATC code
- N07XX05
- Marketing authorisation holder
- SERB SA
- Authorised in the EU since
- 2009
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Firdapse (previously Zenas) used for?
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
What is the active substance in Firdapse (previously Zenas)?
Firdapse (previously Zenas) contains amifampridine.
Who makes Firdapse (previously Zenas)?
The EU marketing authorisation holder is SERB SA.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU